Metropolitan Life Insurance Company (MetLife)’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,029
| Closed | -$56.8K | – | 1723 |
|
|
2024
Q1 | $56.8K | Hold |
3,029
| – | – | ﹤0.01% | 1340 |
|
|
2023
Q4 | $65.6K | Hold |
3,029
| – | – | ﹤0.01% | 1303 |
|
|
2023
Q3 | $62.3K | Buy |
3,029
+138
| +5% | +$3.98K | ﹤0.01% | 1275 |
|
|
2023
Q2 | $136K | Hold |
2,891
| – | – | 0.01% | 871 |
|
|
2023
Q1 | $121K | Sell |
2,891
-257
| -8% | -$11.1K | 0.01% | 908 |
|
|
2022
Q4 | $120K | Hold |
3,148
| – | – | 0.01% | 961 |
|
|
2022
Q3 | $123K | Hold |
3,148
| – | – | 0.01% | 898 |
|
|
2022
Q2 | $102K | Buy |
+3,148
| New | +$106K | ﹤0.01% | 1043 |
|
|
2022
Q1 | – | Sell |
-1,024
| Closed | -$43.6K | – | 2614 |
|
|
2021
Q4 | $43.6K | Buy |
1,024
+3
| +0.3% | +$126 | ﹤0.01% | 2711 |
|
|
2021
Q3 | $45.2K | Sell |
1,021
-41
| -4% | -$1.88K | ﹤0.01% | 2773 |
|
|
2021
Q2 | $60.3K | Sell |
1,062
-172
| -14% | -$12.2K | ﹤0.01% | 2658 |
|
|
2021
Q1 | $92.4K | Buy |
1,234
+25
| +2% | +$2.05K | ﹤0.01% | 2449 |
|
|
2020
Q4 | $105K | Sell |
1,209
-35
| -3% | -$2.58K | ﹤0.01% | 2341 |
|
|
2020
Q3 | $76K | Sell |
1,244
-20
| -2% | -$1.01K | ﹤0.01% | 2366 |
|
|
2020
Q2 | $52.6K | Sell |
1,264
-2,318
| -65% | -$84.1K | ﹤0.01% | 2491 |
|
|
2020
Q1 | $103K | Sell |
3,582
-113
| -3% | -$6.54K | ﹤0.01% | 2010 |
|
|
2019
Q4 | $267K | Sell |
3,695
-20
| -0.5% | -$2.46K | ﹤0.01% | 1718 |
|
|
2019
Q3 | $521K | Buy |
3,715
+128
| +4% | +$21.4K | 0.01% | 1264 |
|
|
2019
Q2 | $657K | Sell |
3,587
-83
| -2% | -$14.2K | 0.01% | 1131 |
|
|
2019
Q1 | $584K | Buy |
3,670
+174
| +5% | +$25.2K | 0.01% | 1196 |
|
|
2018
Q4 | $335K | Sell |
3,496
-12
| -0.3% | -$1.37K | 0.01% | 1483 |
|
|
2018
Q3 | $496K | Sell |
3,508
-69
| -2% | -$10.7K | 0.01% | 1357 |
|
|
2018
Q2 | $560K | Sell |
3,577
-9,489
| -73% | -$1.49M | 0.01% | 1238 |
|
|
2018
Q1 | $2.1M | Buy |
13,066
+1,314
| +11% | +$223K | 0.03% | 505 |
|
|
2017
Q4 | $1.94M | Sell |
11,752
-11,700
| -50% | -$1.13M | 0.03% | 567 |
|
|
2017
Q3 | $1.46M | Hold |
23,452
| – | – | 0.01% | 1055 |
|
|
2017
Q2 | $1.87M | Buy |
23,452
+2,112
| +10% | +$153K | 0.01% | 971 |
|
|
2017
Q1 | $1.52M | Hold |
21,340
| – | – | 0.01% | 1059 |
|
|
2016
Q4 | $1.09M | Buy |
21,340
+1,618
| +8% | +$76.3K | 0.01% | 1252 |
|
|
2016
Q3 | $908K | Hold |
19,722
| – | – | 0.01% | 1340 |
|
|
2016
Q2 | $594K | Buy |
19,722
+7,645
| +63% | +$255K | ﹤0.01% | 1576 |
|
|
2016
Q1 | $387K | Buy |
12,077
+2,335
| +24% | +$82.2K | ﹤0.01% | 1745 |
|
|
2015
Q4 | $568K | Hold |
9,742
| – | – | ﹤0.01% | 1538 |
|
|
2015
Q3 | $412K | Hold |
9,742
| – | – | ﹤0.01% | 1768 |
|
|
2015
Q2 | $711K | Buy |
+9,742
| New | +$626K | 0.01% | 1515 |
|
|
2015
Q1 | – | Sell |
-4,668
| Closed | -$171K | – | 2405 |
|
|
2014
Q4 | $171K | Sell |
4,668
-3,609
| -44% | -$135K | ﹤0.01% | 2515 |
|
|
2014
Q3 | $261K | Buy |
+8,277
| New | +$240K | ﹤0.01% | 2186 |
|
Other funds holding SAGE
RI
BG
Metropolitan Life Insurance Company (MetLife)'s SAGE Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 3,029 shares — an estimated $56.8K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in SAGE in Q3 2014 and held it in 37 quarters. The position peaked at $2.1M in Q1 2018. 194 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 3,029 Sage Therapeutics shares in Q2 2024, an estimated $56.8K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Sage Therapeutics in Q3 2014 and held it in 37 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Sage Therapeutics position peaked at $2.1M in Q1 2018.
- 194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.